- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.02. | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 21.02. | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 19.02. | Verici Dx PLC - Result of General Meeting | 1 | RNS | ||
| 14.02. | Verici DX raises GBP280,000 via retail offer, adding to placing raise | 1 | Alliance News | ||
| 14.02. | Verici Dx PLC - Result of Retail Offer | - | RNS | ||
| 31.01. | EARNINGS AND TRADING: Asia Strategic loss narrows; Verici Dx grant win | 1 | Alliance News | ||
| 31.01. | Verici Dx PLC - Verici Dx announces new research initiative | - | RNS | ||
| 26.01. | Verici Dx PLC - Publication of Circular | - | RNS | ||
| 25.01. | Verici Dx PLC - Launch of Retail Offer | - | RNS | ||
| 24.01. | Verici Dx PLC - Result of Placing | - | RNS | ||
| 24.01. | Verici Dx PLC - Close of Accelerated Bookbuild | - | RNS | ||
| 24.01. | Verici Dx PLC - Proposed Fundraising | - | RNS | ||
| 08.01. | Verici Dx PLC - Medicare National Payment Rate Confirmation | - | RNS | ||
| 08.01. | Verici Dx PLC - CAP accreditation | - | RNS | ||
| 11.12.23 | Verici Dx hails publication of Tutivia data in transplant journal | 1 | Alliance News | ||
| 11.12.23 | Verici Dx PLC - Tutivia validation study published in Journal | - | RNS | ||
| 29.11.23 | Verici Dx PLC - ISO 27001 Information Security Certification | - | RNS | ||
| 20.11.23 | Start-up Verici DX schließt weltweite Lizenz- und Vermarktungsvereinbarung mit Thermo Fisher Scientific | 14 | Bionity.com | ||
| 20.11.23 | Verici Dx PLC - Investor Presentation | - | RNS | ||
| 15.11.23 | Thermo Fisher rises on licensing deal with UK's Verici Dx | 9 | Reuters |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 43,500 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,43 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SPRINGWORKS THERAPEUTICS | 43,320 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,20 | 0,00 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 19,290 | 0,00 % | Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies | Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 25,580 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,790 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| C4 THERAPEUTICS | 6,430 | 0,00 % | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| CG ONCOLOGY | 39,500 | 0,00 % | CG Oncology Inc.: CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 | ||
| AMGEN | 293,20 | +12,92 % | Amgen Aktie: Revolutionäre Therapie gegen Schilddrüsenaugenerkrankung | Der Biotechnologie-Konzern Amgen hat kürzlich Pläne bekannt gegeben, eine Zulassung für sein neuestes Medikament zur Behandlung einer schweren Autoimmunerkrankung bei der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| EVOTEC | 9,855 | -0,40 % | Evotec: Analysten bleiben bullish - Kursziel 2025 | Schwache Konjunkturdaten und Shortseller-Aktivitäten haben eine erste große Erholungsrallye der Evotec-Aktie (WKN: 566480) am gestrigen Donnerstag abgewürgt. Doch aufgeschoben ist nicht aufgehoben.... ► Artikel lesen | |
| ALX ONCOLOGY | 16,620 | 0,00 % | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | ||
| CULLINAN THERAPEUTICS | 27,540 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 4,910 | 0,00 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event | VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,710 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen |
VERICI DX PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,081 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
